Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) EBITDA (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed EBITDA for 8 consecutive years, with -$1.6 million as the latest value for Q4 2025.

  • Quarterly EBITDA changed N/A to -$1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$31.5 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$36.2 million for FY2025, 13.95% up from the prior year.
  • EBITDA for Q4 2025 was -$1.6 million at Actinium Pharmaceuticals, up from -$5.7 million in the prior quarter.
  • The five-year high for EBITDA was -$1.6 million in Q4 2025, with the low at -$16.6 million in Q1 2025.
  • Average EBITDA over 5 years is -$9.3 million, with a median of -$9.6 million recorded in 2024.
  • The sharpest move saw EBITDA crashed 124.32% in 2023, then skyrocketed 54.83% in 2025.
  • Over 5 years, EBITDA stood at -$8.0 million in 2021, then crashed by 40.3% to -$11.3 million in 2022, then grew by 8.4% to -$10.3 million in 2023, then dropped by 21.83% to -$12.6 million in 2024, then soared by 87.06% to -$1.6 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$1.6 million, -$5.7 million, and -$7.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.